Vaccine adjuvant containing lipopolysaccharide and preparation method thereof
The vaccine adjuvant formed solves the problem of low titers of existing antibodies by mixing mineral oil, bacterial lipopolysaccharides, amino acid-based surfactants, polylactic acid-based microspheres and hydrophilic surfactants in a specific proportion, and achieves the problem of low titers of existing antibodies. Efficient immune response and improved antibody levels, with good biocompatibility and stability.
Patent Information
- Application Number
- CN202410975680.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-19
- Publication Date
- 2024-11-12
AI Technical Summary
Existing vaccine adjuvant antibodies containing bacterial lipopolysaccharides have low titers and do not involve the participation of T cells, resulting in low antibacterial titers.
Using vaccine adjuvants composed of mineral oil, bacterial lipopolysaccharides, amino acid-based surfactants, polylactic acid-based microspheres and hydrophilic surfactants, these ingredients are mixed in a specific proportion through the preparation method to form high antibody titers. and stability of vaccine adjuvants.
The antibody level is improved, the immune response to antigen is enhanced, the durability and immune response ability of the antibody is improved, and the vaccine adjuvant has good biocompatibility and stability.
Smart Images

Figure BDA0004954455670000071 
Figure BDA0004954455670000072 
Figure BDA0004954455670000081
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of vaccine adjuvants, and particularly relates to a vaccine adjuvant containing bacterial lipopolysaccharide and a preparation method thereof. Background Art
[0002] Vaccine adjuvant refers to a class of auxiliary substances added during the vaccine preparation process. It does not have the ability to directly resist disease, but can bind to antigens, non-specifically change or enhance the immunogenicity and effectiveness of the vaccine, improve the antigen presentation and processing of the vaccine, activate immune cells, and improve the durability and effectiveness of the immune response.
[0003] Bacterial lipopolysaccharide (LPS) is one of the main components of the cell wall of Gram-negative bacteria. Some LPS are toxic and can produce toxic reactions after infection. This substance is extremely important for human immune response. When the human immune system resists bacterial invasion, LPS is captured by antigen presenting cells (APC) as an important antigen molecule, thereby causing the body's immune response. Lipopolysaccharide is located in the outer wall layer of the Gram-negative bacterial cell wall and is mainly a type of lipopolysaccharide substance. It consists of three parts: lipid A, core polysaccharide and O-specific polysaccharide.
[0004] Based on the good immune activity of bacterial lipopolysaccharide, the existing technology has used it as one of the raw materials for vaccine adjuvants, but its immune activity is mainly achieved by activating B cells to produce antibodies, and this process does not involve the participation of T cells. Therefore, there is a problem of low antibacterial efficacy. Summary of the invention
[0005] The purpose of the present invention is to provide a vaccine adjuvant containing bacterial lipopolysaccharide and a preparation method thereof, and to solve the problem of low antibody titer of existing vaccine adjuvants containing bacterial lipopolysaccharide.
[0006] The purpose of the present invention can be achieved through the following technical solutions:
[0007] A vaccine adjuvant containing bacterial lipopolysaccharide comprises the following raw materials in parts by weight: 50-90 parts of mineral oil, 2.5-5 parts of bacterial lipopolysaccharide, 5-10 parts of amino acid-based surfactant, 3-5 parts of polylactic acid-based microspheres, 7-12 parts of hydrophilic surfactant and 0.5-2 parts of auxiliary agent.
[0008] Further, the amino acid-based surfactant is prepared by the following steps:
[0009] Add alanine and sodium hydroxide into deionized water, stir at room temperature for 10 minutes to obtain an aqueous solution of sodium amino acid, heat to remove water, and obtain a sodium amino acid solid. Place methyl laurate and the sodium amino acid solid in a flask, add polyethylene glycol, and react at 190°C for 6 hours. After cooling to room temperature, add deionized water to dissolve, add hydrochloric acid solution to adjust the pH value to 1-2, and a large amount of precipitate will appear. Filter, wash with water, and dry at 50°C to obtain an amino acid-based surfactant.
[0010] Furthermore, the dosage ratio of alanine, sodium hydroxide and deionized water in the preparation process of sodium amino acid solid is 0.05 mol: 0.05 mol: 10 mL.
[0011] Furthermore, the dosage ratio of methyl laurate, sodium amino acid solid, polyethylene glycol, and deionized water is 10.7 g: 16.9-21.4 g: 50 mL: 200 mL.
[0012] Furthermore, the molecular weight of polyethylene glycol is 200, and the concentration of the hydrochloric acid solution is 1 mol / L.
[0013] Further, polylactic acid-based microspheres are prepared by the following steps:
[0014] The polylactic acid-glycolic acid copolymer was dissolved in dichloromethane, fetal bovine serum was added, and the mixture was centrifuged for 3 minutes. Then, an aqueous solution of hexadecyltrimethylammonium bromide was added dropwise, and the mixture was centrifuged for 5 minutes. The mixture was magnetically stirred for 12 hours at room temperature, and centrifuged for 10 minutes at 4°C. The precipitate was washed twice with 5wt% sucrose water, and then freeze-dried for 72 hours to obtain polylactic acid-based microspheres.
[0015] Furthermore, the dosage ratio of polylactic acid-glycolic acid copolymer, dichloromethane, fetal bovine serum and aqueous solution of cetyltrimethylammonium bromide is 500 mg: 10 mL: 1 mL: 50 mL, and the mass fraction of the aqueous solution of cetyltrimethylammonium bromide is 0.5%.
[0016] Furthermore, the polylactic acid-glycolic acid copolymer is PLGA50:50, with a molecular weight of 60 kd and a characteristic viscosity of 0.45-0.55, purchased from Jinan Daigang Bioengineering Co., Ltd.
[0017] Furthermore, the mineral oil is French Total EOLANE 150 white oil.
[0018] Furthermore, the hydrophilic surfactant is polyoxyethylene sorbitan fatty acid ester T-20.
[0019] Furthermore, the auxiliary agent is selected from one or more of polypropylene glycol PPG200, polypropylene glycol PPG400, vitamin E, squalene and squalane.
[0020] A method for preparing a vaccine adjuvant containing bacterial lipopolysaccharide comprises the following steps:
[0021] According to the formula ratio, mineral oil, bacterial lipopolysaccharide, amino acid-based surfactant, polylactic acid-based microspheres, hydrophilic surfactant and adjuvant are added into a stirrer, and stirred and mixed at a speed of 800-1000 rpm for 10-20 minutes to obtain a vaccine adjuvant containing bacterial lipopolysaccharide.
[0022] Beneficial effects of the present invention:
[0023] The present invention provides a vaccine adjuvant containing bacterial lipopolysaccharide, which is made of mineral oil, bacterial lipopolysaccharide, amino acid-based surfactant, polylactic acid-based microspheres, hydrophilic surfactant, and auxiliary agent, and has the characteristics of good safety, high stability, and high antibody titer;
[0024] Bacterial lipopolysaccharide uses B cells as its main target cells, causing them to clone and proliferate, and inducing the sensitivity of B cells to Th cells, enhancing the immune response to antigens and increasing antibody levels;
[0025] Polylactic acid-based microspheres have good biocompatibility, non-toxicity, good encapsulation and film-forming properties. As vaccine carriers, they have strong adsorption capacity. On the one hand, they can effectively resist enzyme degradation and resist mechanical damage to drugs and vaccines. On the other hand, they increase the surface agent of antigen molecules, improve the immunogenicity of antigen substances, and promote the processing and delivery of antigens by phagocytes.
[0026] Amino acid-based surfactants have good biocompatibility and non-toxic properties. They play an emulsifying role in vaccine adjuvants, and have a synergistic effect with bacterial lipopolysaccharide and polylactic acid-based microspheres to produce a stronger immune response and participate in the cellular immune response, which not only significantly enhances the antibody immune response but also lasts longer. DETAILED DESCRIPTION
[0027] The following will be combined with the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0028] Example 1
[0029] A vaccine adjuvant containing bacterial lipopolysaccharide comprises the following raw materials in parts by weight: 50 parts of mineral oil, 2.5 parts of bacterial lipopolysaccharide, 5 parts of amino acid-based surfactant, 3 parts of polylactic acid-based microspheres, 7 parts of polyoxyethylene sorbitan fatty acid ester T-20, and 0.5 parts of polypropylene glycol PPG200.
[0030] Amino acid based surfactants are prepared by the following steps:
[0031] Add 0.5 mol alanine and 0.5 mol sodium hydroxide to 100 mL deionized water, stir at room temperature for 10 min to obtain an amino acid sodium aqueous solution, heat to remove water, and obtain an amino acid sodium solid. Place 10.7 g methyl laurate and 16.9 g sodium amino acid solid in a flask, add 50 mL polyethylene glycol, react at 190 ° C for 6 h, cool to room temperature, add 200 mL deionized water to dissolve, add hydrochloric acid solution to adjust the pH value to 1, a large amount of precipitate appears, filter, wash with water, and dry at 50 ° C to obtain an amino acid-based surfactant, the molecular weight of polyethylene glycol is 200, and the concentration of the hydrochloric acid solution is 1 mol / L.
[0032] Polylactic acid-based microspheres are made by the following steps:
[0033] 500 mg of polylactic acid-glycolic acid copolymer was dissolved in 10 mL of dichloromethane, 1 mL of fetal bovine serum was added, and the mixture was centrifuged at 13000 × g for 3 min. Then, 50 mL of a 5 wt% aqueous solution of hexadecyltrimethylammonium bromide was added dropwise, and the mixture was centrifuged at 20000 × g for 5 min. The mixture was magnetically stirred at room temperature for 12 h, and centrifuged at 10000 × g and 4°C for 10 min. The precipitate was taken, washed twice with 5 wt% sucrose water, and freeze-dried for 72 h to obtain polylactic acid-based microspheres.
[0034] The polylactic acid-glycolic acid copolymer was PLGA50:50, with a molecular weight of 60 kd and a characteristic viscosity of 0.45-0.55, purchased from Jinan Daigang Bioengineering Co., Ltd.
[0035] The mineral oil is French Total EOLANE 150 white oil.
[0036] A method for preparing a vaccine adjuvant containing bacterial lipopolysaccharide comprises the following steps:
[0037] According to the formula ratio, mineral oil, bacterial lipopolysaccharide, amino acid-based surfactant, polylactic acid-based microspheres, polyoxyethylene sorbitan fatty acid ester T-20, and polypropylene glycol PPG200 were added into a blender, and the mixture was stirred at 800 rpm for 10 min to obtain a vaccine adjuvant containing bacterial lipopolysaccharide.
[0038] Example 2
[0039] A vaccine adjuvant containing bacterial lipopolysaccharide comprises the following raw materials in parts by weight: 60 parts of mineral oil, 4 parts of bacterial lipopolysaccharide, 8 parts of amino acid-based surfactant, 4 parts of polylactic acid-based microspheres, 9 parts of polyoxyethylene sorbitan fatty acid ester T-20, and 1 part of polypropylene glycol PPG400.
[0040] Amino acid based surfactants are prepared by the following steps:
[0041] Add 0.5 mol alanine and 0.5 mol sodium hydroxide to 100 mL deionized water, stir at room temperature for 10 min to obtain an amino acid sodium aqueous solution, heat to remove water, and obtain an amino acid sodium solid. Place 10.7 g methyl laurate and 18.5 g sodium amino acid solid in a flask, add 50 mL polyethylene glycol, react at 190 ° C for 6 h, cool to room temperature, add 200 mL deionized water to dissolve, add hydrochloric acid solution to adjust the pH value to 1, a large amount of precipitate appears, filter, wash with water, and dry at 50 ° C to obtain an amino acid-based surfactant, the molecular weight of polyethylene glycol is 200, and the concentration of the hydrochloric acid solution is 1 mol / L.
[0042] Polylactic acid-based microspheres are made by the following steps:
[0043] 500 mg of polylactic acid-glycolic acid copolymer was dissolved in 10 mL of dichloromethane, 1 mL of fetal bovine serum was added, and the mixture was centrifuged at 13000 × g for 3 min. Then, 50 mL of a 5 wt% aqueous solution of hexadecyltrimethylammonium bromide was added dropwise, and the mixture was centrifuged at 20000 × g for 5 min. The mixture was magnetically stirred at room temperature for 12 h, and centrifuged at 10000 × g and 4°C for 10 min. The precipitate was taken, washed twice with 5 wt% sucrose water, and freeze-dried for 72 h to obtain polylactic acid-based microspheres.
[0044] The polylactic acid-glycolic acid copolymer was PLGA50:50, with a molecular weight of 60 kd and a characteristic viscosity of 0.45-0.55, purchased from Jinan Daigang Bioengineering Co., Ltd.
[0045] The mineral oil is French Total EOLANE 150 white oil.
[0046] A method for preparing a vaccine adjuvant containing bacterial lipopolysaccharide comprises the following steps:
[0047] According to the formula ratio, mineral oil, bacterial lipopolysaccharide, amino acid-based surfactant, polylactic acid-based microspheres, polyoxyethylene sorbitan fatty acid ester T-20, and polypropylene glycol PPG400 were added into a stirrer, and the mixture was stirred at 900 rpm for 15 minutes to obtain a vaccine adjuvant containing bacterial lipopolysaccharide.
[0048] Example 3
[0049] A vaccine adjuvant containing bacterial lipopolysaccharide comprises the following raw materials in parts by weight: 90 parts of mineral oil, 5 parts of bacterial lipopolysaccharide, 10 parts of amino acid-based surfactant, 5 parts of polylactic acid-based microspheres, 12 parts of polyoxyethylene sorbitan fatty acid ester T-20, and 2 parts of vitamin E.
[0050] Amino acid based surfactants are prepared by the following steps:
[0051] Add 0.5 mol alanine and 0.5 mol sodium hydroxide to 100 mL deionized water, stir at room temperature for 10 min to obtain an amino acid sodium aqueous solution, heat to remove water, and obtain an amino acid sodium solid. Place 10.7 g methyl laurate and 21.4 g sodium amino acid solid in a flask, add 50 mL polyethylene glycol, react at 190 ° C for 6 h, cool to room temperature, add 200 mL deionized water to dissolve, add hydrochloric acid solution to adjust the pH value to 2, a large amount of precipitate appears, filter, wash with water, and dry at 50 ° C to obtain an amino acid-based surfactant, the molecular weight of polyethylene glycol is 200, and the concentration of the hydrochloric acid solution is 1 mol / L.
[0052] Polylactic acid-based microspheres are made by the following steps:
[0053] 500 mg of polylactic acid-glycolic acid copolymer was dissolved in 10 mL of dichloromethane, 1 mL of fetal bovine serum was added, and the mixture was centrifuged at 13000 × g for 3 min. Then, 50 mL of a 5 wt% aqueous solution of hexadecyltrimethylammonium bromide was added dropwise, and the mixture was centrifuged at 20000 × g for 5 min. The mixture was magnetically stirred at room temperature for 12 h, and centrifuged at 10000 × g and 4°C for 10 min. The precipitate was taken, washed twice with 5 wt% sucrose water, and freeze-dried for 72 h to obtain polylactic acid-based microspheres.
[0054] The polylactic acid-glycolic acid copolymer was PLGA50:50, with a molecular weight of 60 kd and a characteristic viscosity of 0.45-0.55, purchased from Jinan Daigang Bioengineering Co., Ltd.
[0055] The mineral oil is French Total EOLANE 150 white oil.
[0056] A method for preparing a vaccine adjuvant containing bacterial lipopolysaccharide comprises the following steps:
[0057] According to the formula ratio, mineral oil, bacterial lipopolysaccharide, amino acid-based surfactant, polylactic acid-based microspheres, polyoxyethylene sorbitan fatty acid ester T-20, and vitamin E were added to a blender, and the mixture was stirred at 1000 rpm for 20 minutes to obtain a vaccine adjuvant containing bacterial lipopolysaccharide.
[0058] Comparative Examples 1-3
[0059] Compared with Example 1, the difference is that the weight parts of bacterial lipopolysaccharide, amino acid-based surfactant, and polylactic acid-based microspheres in Comparative Examples 1-3 are as shown in Table 1, and the other operating steps and parameters remain unchanged.
[0060] Table 1
[0061]
[0062] Test Example 1
[0063] 500 g of the vaccine adjuvant prepared in the embodiment and the comparative example was sterilized by high-pressure steam at 121° C. for 30 min, cooled naturally, and placed in an emulsification tank, and the temperature in the emulsification tank was controlled to be 30±2° C.; 500 g of foot-and-mouth disease antigen (inactivated, antigen content 4.69 μg / mL) was heated to 30±2° C. and then added to the emulsification tank; the mixture of the vaccine adjuvant and the aqueous phase antigen was emulsified at an emulsification speed of 400 rpm, an emulsification temperature of 30±2° C., and an emulsification time of 30 min. After the emulsification was completed, the foot-and-mouth disease vaccine was obtained.
[0064] Physical property test of foot-and-mouth disease vaccine: The foot-and-mouth disease vaccine obtained by each group of vaccine adjuvants was centrifuged at 3000 rpm for 15 min to observe whether it was stratified and precipitated, and whether it was demulsified after being placed at 37°C for 10 days. The test results are shown in Table 2;
[0065] Table 2
[0066]
[0067] It can be seen from the data recorded in Table 2 that, compared with Comparative Example 1, the vaccines obtained in Examples 1-3 and Comparative Examples 2-3 have better stability, indicating that the introduction of the amino acid-based surfactant in the present invention can effectively improve the stability of the vaccine;
[0068] Evaluation of the efficacy of foot-and-mouth disease vaccine: 60 18-22 g mice (Kunming mice, female, clean grade) were randomly divided into 6 groups, 10 mice in each group, and the six groups of mice were subcutaneously injected, and the scheme was as follows: the foot-and-mouth disease vaccine prepared in this embodiment and the comparative example was inoculated, and the inoculation dose was 0.5 mL / mouse; 21 days after immunization, the three groups of mice were tail-cut and blood was collected, and the serum was separated to detect the foot-and-mouth disease antibody titer in the serum. The test results are shown in Table 3:
[0069] Table 3
[0070]
[0071] It can be seen from Table 3 that compared with Comparative Examples 1-3, the antibody titer of the vaccine adjuvant described in Examples 1-3 is higher, indicating that the amino acid-based surfactant, bacterial lipopolysaccharide, and polylactic acid-based microspheres in the present invention play a synergistic role, produce a stronger immune response, participate in the cellular immune response, and not only significantly enhance the antibody immune response, but also for a longer time.
[0072] It should be noted that, in this article, relational terms such as first and second, etc. are only used to distinguish one entity or operation from another entity or operation, and do not necessarily require or imply any such actual relationship or order between these entities or operations. Moreover, the terms "include", "comprise" or any other variants thereof are intended to cover non-exclusive inclusion, so that a process, method, article or device including a series of elements includes not only those elements, but also other elements not explicitly listed, or also includes elements inherent to such process, method, article or device.
[0073] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.
Claims
1. A vaccine adjuvant containing bacterial lipopolysaccharide, characterized in that: The invention comprises the following raw materials in parts by weight: 50-90 parts of mineral oil, 2.5-5 parts of bacterial lipopolysaccharide, 5-10 parts of amino acid-based surfactant, 3-5 parts of polylactic acid-based microspheres, 7-12 parts of hydrophilic surfactant and 0.5-2 parts of auxiliary agent.
2. A vaccine adjuvant containing bacterial lipopolysaccharide according to claim 1, characterized in that: Amino acid based surfactants are prepared by the following steps: Add alanine and sodium hydroxide into deionized water, stir at room temperature for 10 minutes to obtain an aqueous solution of sodium amino acid, heat to remove water, and obtain a sodium amino acid solid. Place methyl laurate and the sodium amino acid solid in a flask, add polyethylene glycol, and react at 190°C for 6 hours. After cooling to room temperature, add deionized water to dissolve, add hydrochloric acid solution to adjust the pH value to 1-2, and a large amount of precipitate will appear. Filter, wash with water, and dry at 50°C to obtain an amino acid-based surfactant.
3. A vaccine adjuvant containing bacterial lipopolysaccharide according to claim 2, characterized in that: The dosage ratio of alanine, sodium hydroxide and deionized water in the preparation process of sodium amino acid solid is 0.05 mol: 0.05 mol: 10 mL.
4. A vaccine adjuvant containing bacterial lipopolysaccharide according to claim 2, characterized in that: The dosage ratio of methyl laurate, sodium amino acid solid, polyethylene glycol, and deionized water is 10.7 g: 16.9-21.4 g: 50 mL: 200 mL.
5. A vaccine adjuvant containing bacterial lipopolysaccharide according to claim 1, characterized in that: Polylactic acid-based microspheres are made by the following steps: The polylactic acid-glycolic acid copolymer was dissolved in dichloromethane, fetal bovine serum was added, and the mixture was centrifuged for 3 minutes. Then, an aqueous solution of hexadecyltrimethylammonium bromide was added dropwise, and the mixture was centrifuged for 5 minutes. The mixture was magnetically stirred for 12 hours at room temperature, and centrifuged for 10 minutes at 4°C. The precipitate was washed twice with 5wt% sucrose water, and then freeze-dried for 72 hours to obtain polylactic acid-based microspheres.
6. A vaccine adjuvant containing bacterial lipopolysaccharide according to claim 5, characterized in that: The dosage ratio of polylactic acid-glycolic acid copolymer, dichloromethane, fetal bovine serum and aqueous solution of hexadecyltrimethylammonium bromide is 500 mg: 10 mL: 1 mL: 50 mL, and the mass fraction of the aqueous solution of hexadecyltrimethylammonium bromide is 0.5%.
7. The method for preparing a vaccine adjuvant containing bacterial lipopolysaccharide according to claim 1, characterized in that: The following steps are involved: According to the formula ratio, mineral oil, bacterial lipopolysaccharide, amino acid-based surfactant, polylactic acid-based microspheres, hydrophilic surfactant and adjuvant are added into a stirrer, and stirred and mixed at a speed of 800-1000 rpm for 10-20 minutes to obtain a vaccine adjuvant containing bacterial lipopolysaccharide.
